Free Trial
NASDAQ:LSTA

Lisata Therapeutics (LSTA) Stock Price, News & Analysis

Lisata Therapeutics logo
$2.51 -0.02 (-0.79%)
Closing price 08/26/2025 04:00 PM Eastern
Extended Trading
$2.58 +0.07 (+2.79%)
As of 07:03 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Lisata Therapeutics Stock (NASDAQ:LSTA)

Key Stats

Today's Range
$2.45
$2.61
50-Day Range
$2.39
$2.96
52-Week Range
$1.87
$4.20
Volume
13,157 shs
Average Volume
32,546 shs
Market Capitalization
$21.98 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$23.50
Consensus Rating
Buy

Company Overview

Lisata Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
46th Percentile Overall Score

LSTA MarketRank™: 

Lisata Therapeutics scored higher than 46% of companies evaluated by MarketBeat, and ranked 444th out of 929 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Lisata Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Lisata Therapeutics has only been the subject of 2 research reports in the past 90 days.

  • Read more about Lisata Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Lisata Therapeutics are expected to grow in the coming year, from ($2.66) to ($2.36) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Lisata Therapeutics is -1.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Lisata Therapeutics is -1.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Lisata Therapeutics has a P/B Ratio of 1.06. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Lisata Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    0.70% of the float of Lisata Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Lisata Therapeutics has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Lisata Therapeutics has recently increased by 61.82%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Lisata Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Lisata Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.70% of the float of Lisata Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Lisata Therapeutics has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Lisata Therapeutics has recently increased by 61.82%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Lisata Therapeutics has a news sentiment score of 0.95. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 9 news articles for Lisata Therapeutics this week, compared to 2 articles on an average week.
  • MarketBeat Follows

    2 people have added Lisata Therapeutics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Lisata Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 9.10% of the stock of Lisata Therapeutics is held by insiders.

  • Percentage Held by Institutions

    Only 8.94% of the stock of Lisata Therapeutics is held by institutions.

  • Read more about Lisata Therapeutics' insider trading history.
Receive LSTA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lisata Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

LSTA Stock News Headlines

Q3 EPS Estimate for Lisata Therapeutics Increased by Analyst
BREAKING: The House just passed 3 pro-crypto bills!
THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. tc pixel
See More Headlines

LSTA Stock Analysis - Frequently Asked Questions

Lisata Therapeutics' stock was trading at $2.98 at the beginning of the year. Since then, LSTA shares have decreased by 15.8% and is now trading at $2.51.

Lisata Therapeutics, Inc. (NASDAQ:LSTA) issued its quarterly earnings results on Thursday, August, 7th. The company reported ($0.54) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.65) by $0.11. The business earned $0.07 million during the quarter.
Read the conference call transcript
.

Top institutional investors of Lisata Therapeutics include BML Capital Management LLC (2.40%) and Cerity Partners LLC (0.14%).

Shares of LSTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Lisata Therapeutics investors own include PayPal (PYPL), JD.com (JD), NIO (NIO), Construction Partners (ROAD), Sunrun (RUN), ASE Technology (ASX) and Coinbase Global (COIN).

Company Calendar

Last Earnings
8/07/2025
Today
8/27/2025
Next Earnings (Estimated)
11/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:LSTA
CIK
320017
Employees
30
Year Founded
N/A

Price Target and Rating

High Price Target
$32.00
Low Price Target
$15.00
Potential Upside/Downside
+836.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

EPS (Trailing Twelve Months)
($2.23)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$19.99 million
Net Margins
N/A
Pretax Margin
-1,858.41%
Return on Equity
-69.68%
Return on Assets
-59.44%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
5.77
Quick Ratio
5.77

Sales & Book Value

Annual Sales
$1.07 million
Price / Sales
20.54
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.37 per share
Price / Book
1.06

Miscellaneous

Outstanding Shares
8,756,000
Free Float
7,959,000
Market Cap
$21.98 million
Optionable
Not Optionable
Beta
0.93
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

This page (NASDAQ:LSTA) was last updated on 8/27/2025 by MarketBeat.com Staff
From Our Partners